Amarin Corp Plc (AMRN)

[rosemountbomber]

I assume you are referring to slide 11. I think that, like you say, they are trying to show the potential for Europe. Matter of fact they have a bullet point on the slide:

Key takeaway for Europe & RoW: With time to
promote and educate, providers respond
favorably to VASCEPA/VAZKEPA as a therapy that
can benefit their patients.

Of course you would think savvy investors would not be so dumb as to think those results can be duplicated in the EU wrt sales and time. No advertising in the EU so it will be a slower uptake. Not to mention of course that we can't get all the countries to reimburse yet. And ProLiberty is not wrong when he says they want to make sure everyone knows the strong uptake V had before the Generics entered.

Another slide that showed V's uptake here was slide 43. They were attempting to show two things there, first the strong uptake after R-I, and secondly that after 3 years they are about even with Generics or slightly ahead. Doubt that they will trot out that graph in another year or two since it looks like market share of US scripts will continue to erode.